Department of Cardiology, National Hospital Organization, Kanmon Medical Center, 1-1 Chofusotoura-cho, Shimonoseki, Yamaguchi 752-8510, Japan.
J Cardiol. 2010 Mar;55(2):174-9. doi: 10.1016/j.jjcc.2009.10.006. Epub 2009 Dec 1.
Contrast-induced nephropathy (CIN) is one of the important complications of coronary angiography (CAG) and percutaneous coronary intervention (PCI), especially in patients with chronic kidney disease (CKD). Prophylactic administration of N-acetylcysteine (NAC) and aminophylline has been reported to be effective in some trials, but the results still remain controversial. We investigated the efficacy of NAC or aminophylline in preventing CIN.
Forty-five consecutive patients undergoing CAG and/or PCI were randomly assigned to receive hydration and NAC (704 mg orally twice daily; NAC group, n=15), hydration and aminophylline (250 mg intraveneously 30 min before CAG and/or PCI; aminophylline group, n=15), or hydration alone (control group, n=15). We compared serum creatinine (SCr), creatinine clearance (Ccr), blood beta-2 microglobulin, and urinary beta-2 microglobulin levels at baseline and 48h after CAG and/or PCI. In the NAC group, SCr decreased from 1.00 + or - 0.36 to 0.67 + or - 0.16 mg/dl (p<0.01), and Ccr significantly increased from 62.4 + or - 15.6 to 80.4 + or - 8.39 ml/min (p<0.01). In the aminophylline group, SCr and Ccr were unchanged. In the control group, SCr significantly increased from 0.94 + or - 0.21 to 1.28 + or - 0.21 mg/dl (p<0.01), and Ccr significantly decreased from 63.7 + or - 16.1 to 46.1 + or - 10.6 ml/min (p<0.01) after CAG and/or PCI. In the NAC group, mean blood beta-2 microglobulin significantly decreased from 2.38 + or - 0.58 to 1.71 + or - 0.38 mg/dl (p<0.01), and in the aminophylline group, mean urinary beta-2 microglobulin concentration significantly decreased from 337 + or - 31.0 to 239 + or - 34 microg/ml (p<0.01).
These results suggest that both prophylactic NAC and aminophylline administration are effective in preventing CIN, but not with hydration alone. It appears that the two compounds work in different ways against CIN.
对比剂肾病(CIN)是冠状动脉造影(CAG)和经皮冠状动脉介入治疗(PCI)的重要并发症之一,尤其在慢性肾脏病(CKD)患者中。已有研究报道,预防性应用 N-乙酰半胱氨酸(NAC)和氨茶碱可有效预防 CIN,但结果仍存在争议。本研究旨在探讨 NAC 或氨茶碱预防 CIN 的疗效。
连续 45 例接受 CAG 和/或 PCI 的患者被随机分为三组:水化+NAC 组(704mg 口服,每日 2 次,n=15)、水化+氨茶碱组(250mg 静脉注射,CAG 和/或 PCI 前 30min,n=15)和单纯水化组(n=15)。比较三组患者 CAG 和/或 PCI 前及术后 48h 血清肌酐(SCr)、肌酐清除率(Ccr)、血β2-微球蛋白和尿β2-微球蛋白水平。NAC 组患者 SCr 由 1.00+0.36mg/dl 降至 0.67+0.16mg/dl(p<0.01),Ccr 由 62.4+15.6ml/min 升高至 80.4+8.39ml/min(p<0.01)。氨茶碱组患者 SCr 和 Ccr 无明显变化。单纯水化组患者 CAG 和/或 PCI 后 SCr 由 0.94+0.21mg/dl 升高至 1.28+0.21mg/dl(p<0.01),Ccr 由 63.7+16.1ml/min 降低至 46.1+10.6ml/min(p<0.01)。NAC 组患者血β2-微球蛋白由 2.38+0.58mg/dl 降至 1.71+0.38mg/dl(p<0.01),氨茶碱组患者尿β2-微球蛋白浓度由 337+31.0μg/ml 降至 239+34μg/ml(p<0.01)。
预防性应用 NAC 和氨茶碱可有效预防 CIN,但单纯水化治疗无效。这两种药物可能通过不同的机制预防 CIN。